A randomized research study sponsored by Washington University School of Medicine seeks participants age 30 and older, who have tested positive for COVID-19, and are currently experiencing mild symptoms.
The purpose of the study is to determine if the drug fluvoxamine can be used during the early onset of COVID-19 infections to prevent more severe symptoms such as shortness of breath. Fluvoxamine is an anti-depressant drug approved by the US Food and Drug Administration (FDA) for the treatment of obsessive-compulsive disorder. The FDA has not approved fluvoxamine for COVID-19 treatment and therefore its use for the treatment of COVID-19 is considered investigational.
The study will be entirely remote, meaning that there will be no face-to-face contact. Materials, including the study drug, will be shipped to participants’ houses. All communication and interactions will be done via videoconferencing, email, or phone. People living in the United States and Canada can participate.
Study Contact: Contact: Angela Stevens (314) 362-6291, email@example.com